In the recent publication, Zebrafish as an in vivo screening tool to establish PARP inhibitor efficacy, researchers examined treatment modalities to aid the development of PARP inhibitors. These compounds target tumors deficient in the Homologous Recombination pathway, which are associated with increased risk for breast, ovarian, pancreatic and prostate cancer.
See more below and the full article here.
Contact Us
Xstrahl presented The role of radiation technologists as a radiotherapy treatment at the 11th Congress of Radiological Technologists of R. N. Macedonia
Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, will demonstrate Xstrahl 200, a modern orthovoltage radiotherapy solution for treating superficial lesions, skin cancers, and selective benign conditions at the 2024 American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Meeting in Washington, DC Sept. 29-Oct 2, 2024, at booth #1937.
Xstrahl, the leader in preclinical radiation research systems, will demonstrate SmART-RAD at the 70th Annual Meeting of the Radiation Research Society (RRS) at the Westin La Paloma Resort & Spa, in Tucson, AZ, Sept. 15-18.
